Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2401 to 2415 of 8963 results

  1. Gambling

    Awaiting development Reference number: GID-QS10099 Expected publication date: TBC

    Quality standard
    Awaiting development

  2. Prevention of dementia

    Awaiting development Reference number: GID-QS10109 Expected publication date: TBC

    Quality standard
    Awaiting development

  3. Readmission to ICU within 48hrs

    Awaiting development Reference number: GID-QS10105 Expected publication date: TBC

    Quality standard
    Awaiting development

  4. Primary hyperparathyroidism

    Awaiting development Reference number: GID-QS10089 Expected publication date: TBC

    Quality standard
    Awaiting development

  5. Total hip arthroplasty using the superpath approach for osteoarthritis

    In development Reference number: GID-IPG10204 Expected publication date: TBC

    Interventional procedures guidance
    In development

  6. Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687]

    In development Reference number: GID-TA10664 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Obeticholic acid for treating liver fibrosis in people with steatohepatitis [ID1645]

    In development Reference number: GID-TA10606 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Indoor air quality at home

    In development Reference number: GID-QS10113 Expected publication date: TBC

    Quality standard
    In development

  9. SpaceOAR hydrogel spacer for reducing rectal toxicity during radiotherapy for prostate cancer (Suspended – referred to technology appraisals)

    In development Reference number: GID-MT526 Expected publication date: TBC

    Medical technologies guidance
    In development

  10. Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261]

    In development Reference number: GID-TA10250 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Mepolizumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils [ID1237]

    In development Reference number: GID-TA10239 Expected publication date:  06 August 2026

    Technology appraisal guidance
    In development

  12. Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [ID1259]

    In development Reference number: GID-TA10225 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. NY-ESO-1 T-cells for treating synovial sarcoma [ID1286]

    In development Reference number: GID-TA10205 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Managing common infections - antimicrobial prescribing guidelines

    In development Reference number: GID-NG10050 Expected publication date: TBC

    NICE guideline
    In development

  15. Melanoma (metastatic) - talimogene laherparepvec [ID508]

    In development Reference number: GID-TAG509 Expected publication date:  28 September 2016

    Technology appraisal guidance
    In development